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Abstract
Objective: Alpha-tocopherol is the main vitamin E compound in humans, and has important antioxidative and
immunomodulatory properties. The aim of this study was to study alpha-tocopherol concentrations and their relationship
to disease activity in Norwegian multiple sclerosis (MS) patients.
Methods: Prospective cohort study in 88 relapsing-remitting MS (RRMS) patients, originally included in a randomised
placebo-controlled trial of omega-3 fatty acids (the OFAMS study), before and during treatment with interferon beta. The
patients were followed for two years with repeated 12 magnetic resonance imaging (MRI) scans and nine serum
measurements of alpha-tocopherol.
Results: During interferon beta (IFNB) treatment, each 10 mmol/L increase in alpha-tocopherol reduced the odds (CI 95%)
for simultaneous new T2 lesions by 36.8 (0.5–59.8) %, p = 0.048, and for combined unique activity by 35.4 (1.6–57.7) %,
p = 0.042, in a hierarchical regression model. These associations were not significant prior to IFNB treatment, and were not
noticeably changed by gender, age, body mass index, HLA-DRB1*15, treatment group, compliance, or the concentrations of
25-hydroxyvitamin D, retinol, neutralising antibodies against IFNB, or the omega-3 fatty acids eicosapentaenoic acid and
docosahexaenoic acid. The corresponding odds for having new T1 gadolinium enhancing lesions two months later was
reduced by 65.4 (16.5–85.7) %, p = 0.019, and for new T2 lesions by 61.0 (12.4–82.6) %, p = 0.023.
Conclusion: During treatment with IFNB, increasing serum concentrations of alpha-tocopherol were associated with
reduced odds for simultaneous and subsequent MRI disease activity in RRMS patients.
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Introduction
Vitamin E is an essential nutritional factor found in vegetable
oils and margarines, vegetables, fruits, nuts and to some extent fish
[1]. Natural vitamin E comprises eight different compounds, of
which alpha-tocopherol is the most abundant in human blood and
has the highest biological potency [2]. Vitamin E has antioxidative
and immunomodulatory properties and is considered one of the
most important antioxidative factors against reactive oxygen
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species (ROS) overload and damages from oxidative stress [3].
ROS and oxidative stress have been incriminated in the
pathogenesis of several diseases, including neurodegenerative
disease and multiple sclerosis (MS) [4].
Vitamin E is shown to affect different immune cells. In mice,
vitamin E enhanced naı¨ve T cell function by increasing division
and interleukin-2 production, and by reducing T cell suppressive
prostaglandin E2 from macrophages [3]. Moreover, appropriate
function and interaction between CD8+ T cells, dendritic cells and
T regulatory cells in response to viral infection depend on
adequate vitamin E levels [5]. In murine microglia cultures,
vitamin E has been shown to induce morphological changes and
down regulate different adhesions molecules, both associated with
deactivation [6]. Treatment with vitamin E also inhibited
demyelination caused by ethidium bromide [7], increased
subsequent remyelination (7), and has been shown to exert dose-
dependent effects in a murine lupus model [8].
The effect of interferon beta (IFNB) in MS is only partial, and
antioxidant therapy might potentially be an adjuvant. IFNB
treatment was associated with higher concentrations of alpha-
tocopherol in plasma of MS patients compared to controls [9], and
also with normalization of the alpha-tocopherol levels in erythro-
cytes [10].
In spite of relevant biological properties, the relationship
between vitamin E and disease activity in MS has not been
investigated. To chart the vitamin E levels and their relationship to
disease activity in Norwegian MS patients, we have measured
alpha-tocopherol in serum samples from 88 relapsing-remitting
MS (RRMS) patients who participated in a randomised placebo-
controlled trial of supplementation with omega-3 fatty acids or
placebo in RRMS patients before and during treatment with
IFNB (the OFAMS study) [11]. The patients were followed for two
years with repeated and corresponding magnetic resonance
imaging (MRI) scans and serum sampling, as well as registration
of clinical disease activity.
Methods
The design and the results of the OFAMS study have been
presented previously [11]. In brief, 88 RRMS patients were
allocated to either omega-3 fatty acids (Triomar) or placebo
(corn oil), and followed for two years with repeated and
corresponding MRI scans and serum sampling. None of the
patients had received treatment with immunomodulatory agents
six months prior to inclusion. All patients were initiated on
interferon beta-1a (IFNB) at study month 6. The MRI scans were
conducted monthly from baseline to study month 9, thereafter at
month 12 and 24, and evaluated blindly and independently by two
experienced neuro-radiologists for new T1 gadolinium (Gd+)
enhancing lesions, new T2 lesions and combined unique activity
(CUA; sum of T1Gd+ lesions and new or enlarging T2 lesions) as
previously described [11,12]. The serum samples were collected at
baseline, thereafter at month 1, 3, 6, 7, 9, 12, 18 and 24 and
analysed for alpha-tocopherol. The omega-3 fatty acids eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA) were
analysed at baseline and month 6, 12 and 24. Both the omega-3
fatty acid and the placebo preparations were added vitamin E in
order to protect the fatty acids against oxidation. The omega-3
fatty acid capsules contained four IU alpha-tocopherol, which
equals approximately 13 mg per daily dose. The placebo
preparation contained mixed tocopherols of which approximately
22 mg per daily dose were alpha-tocopherol. Neither of the
preparations contained vitamin D nor A. The Expanded Disability
Status Scale (EDSS) score was evaluated every sixth months and
relapses were recorded throughout the study period.
Analyses
Serum samples were stored at 280uC until analysis, which was
performed simultaneously by blinded lab-technicians for all
samples from each patient. The concentration of alpha-tocopherol
was measured at Department of Medical Biochemistry, St. Olavs`
Hospital, Trondheim University Hospital, using an Agilent 100
high performance liquid chromatography (HPLC) system
equipped with a diode array detector (Agilent Technologies,
Santa Clara, CA USA) and the Reagent kit for the HPLC
determination of alpha-tocopherol in serum (CHROMSYSTEMS
Instruments & Chemicals GmbH, Mu¨nchen, Germany). The
within run coefficient of variation was 0.7% at 30.9 mmol alpha-
tocopherol/L and the day-to-day coefficient of variation was 3.0%
at 41.8 mmol alpha-tocopherol/L. Neutralising antibodies (NAb)
against IFNB were analysed by real time quantitative polymerase
chain reaction at study month 24, and categorized as negative,
intermediate or high. The analyses of 25-hydoxyvitamin D,
retinol, EPA, DHA and HLA-DRB1*15 has been described
previously [11,12,13].
Statistics
As the MRI outcomes were skewed towards none or one lesion,
they were dichotomised as present or absent. We addressed our
research question by using a hierarchical logistic regression model
as previously described [12]. This model takes into account the
repeated MRI scans and serum measurements within a patient.
The SAS GLIMMIX procedure was used to fit the model with
random intercepts for patients and fixed effects of alpha-
tocopherol. Only paired measurements of alpha-tocopherol and
MRI scans were included in the regression model. The same
statistical model was used to analyse the association between
alpha-tocopherol and MRI outcomes lagged by 1 and 2 study
months after the alpha-tocopherol measurements. Gender, age,
body mass index (BMI), HLA-DRB1*15 status, treatment group
(omega-3 or placebo), compliance (intake of study medication in
percentage of the total dosage) and serum concentrations of 25-
hydroxyvitamin D, retinol, EPA and DHA and NAb against IFNB
(categorized as negative, low to moderate and high concentration)
were included as possible predictors to the logistic regression
model. The Pearson’s correlation coefficient (r) was calculated to
examine the association between baseline values of alpha-
tocopherol and the cumulative number of new T1Gd+ and T2
lesions and CUA. Independent samples t-test was used for the
comparison of means. Mean (SD) values are presented unless
otherwise stated. The statistical analyses were conducted using
SAS version 9.2 and SPSS version 15.0. Findings with p,0.05
were considered significant.
Missing Values
Twelve alpha-tocopherol, 25-hydroxyvitamin D and retinol
values were missing (one at baseline, three during study months 1–
6 and eight during study months 7–24). Twenty-three MRI scans
were missing (14 during study months 1–6, nine during study
months 7–24). We defined MRI scans and serum samples
collected within an interval of one month as paired, and 11
MRI/alpha-tocopherol measurements that exceeded this limit
were excluded from analysis. EDTA-blood for HLA-DRB1 typing
was missing for four, and BMI was missing for two patients. EDSS
scores were missing for two patients at month 24. Missing values
were not replaced.
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Ethics Statement
The study was approved by the Regional Committee for
Medical and Health Research Ethics in Western Norway Regional
Health Authority. All participants gave written informed consent.
Results
Patient Population
Eighty-eight RRMS patients, 57 (65%) women and 31 (35%)
men, 58 (66%) HLA-DRB1*15 positive, age 38.9 (8.3) years, BMI
25.7 (4.3), disease duration 1.9 (3.1) years, and EDSS score at
baseline of 1.9 (0.8) were included in the study.
Alpha-tocopherol Status
From the whole study period (study months 0–24) there were
780 measurements of alpha-tocopherol. The mean baseline
concentration of alpha tocopherol was 29.5 (7.3) mmol/L and
the mean concentration during the rest of the study was 32.4 (0.76)
mmol/L (p,0.001 for difference). The mean difference between
concentrations at baseline and through the rest of the study period
was 2.0 (3.9) mmol/L for the patients treated with omega-3 fatty
acids (n = 46) and 4.5 (3.8) mmol/L for the placebo group (n= 41)
(p = 0.003 for difference). There were no significant differences
before and during IFNB treatment or between genders, or any
seasonal variation (Figure 1). The mean ratio between the highest
and the lowest concentration of alpha-tocopherol (baseline not
included) in each patient was 1.34 (0.22). The intraclass
correlation coefficient was 0.788, which implies that 21.2% of
the total variance in alpha-tocopherol concentrations was
explained by intra-individual variation. The reference range for
alpha-tocopherol is 10.5–43.5 mmol/L, and 728 (93.3%) of all the
measurements were within this interval. None of the measure-
ments were below the reference range, whereas 52 (6.7%) were
above 43.5 mmol/L.
MRI Outcomes
From the whole study period, a total of 587 paired MRI scans
and alpha-tocopherol measurements (interval 3.4 (5.3) days), of
which 254 were collected before and 333 after initiation of IFNB
treatment, were available for analysis (table 1). During IFNB
treatment, the odds (CI 95%) for new T2 lesions and CUA were
significantly reduced by 36.8 (0.5–59.8) % and 35.4 (1.6–57.7) %
with each 10 mmol/L increase in alpha-tocopherol, whereas no
significant association was found before IFNB treatment or for the
whole study period. It has previously been reported higher
concentrations of alpha-tocopherol in women compared to men,
and an inverse relationship with BMI [14]. Adjusting for gender,
age and BMI did not noticeably change our results.
HLA DRB1*15 is the main genetic risk factor for MS and may
interact with environmental risk factors [15]. We have previously
reported that vitamin D [12] and vitamin A [13] levels were
inversely associated with MRI activity. Supplementation with EPA
and DHA did not influence disease activity in the same patients
[11], although EPA and DHA have been suggested to affect the
disease course of MS in other studies [16]. Furthermore, the fat
soluble vitamins and also the omega-3 fatty acid have some
overlapping dietary sources [1,17]. The associations between
alpha-tocopherol and MRI outcomes were only significant during
IFNB treatment. Thus, NAb against IFNB could potentially have
influenced the results. As the omega-3 and placebo preparations
contained alpha-tocopherol, treatment group (omega-3 or place-
bo) and compliance could potentially also have confounded the
results. To exclude that the results were influenced by these
factors, 25-hydroxyvitamin D and retinol (measured in all serum
samples) and EPA and DHA (measured at month 6, 12, and 24),
treatment group, compliance, and the concentration of NAb
against IFNB (no, intermediate or high) were entered into the
logistic regression model. Entering these variables separately or
together did not significantly change the results (data not shown).
To examine whether higher alpha-tocopherol levels protect
against subsequent disease activity, we also examined if the
baseline concentration correlated with the cumulative number of
MRI lesions during the study period. For all MRI outcomes, there
was a non-significant trend for a negative correlation (CI 95%)
with the baseline alpha-tocopherol level (r =20.12 (20.31–0.09)
for new T1Gd+ lesions, 20.15 (20.35–0.06) for new T2 lesions,
and 20.16 (20.36–0.05) for CUA).
To examine whether alpha-tocopherol predict subsequent MRI
disease activity, we analysed the association with MRI outcomes
lagged by one (31.2 (6.6) days) and two (62.1 (7.1) days) study
months. During IFNB treatment, the odds (CI 95%) for new
T1Gd+ lesions two months later was reduced by 65.4 (16.5–85.7)
%, and for new T2 lesions by 61.0 (12.4–82.6) % with each
10 mmol/L increase in alpha-tocopherol (table 2).
Clinical Disease Activity
The mean concentration of alpha-tocopherol was 30.95 (1.22)
mmol/L in the 23 patients who experienced at least one relapse
during the study period and 32.85 (0.93) mmol/L in the 65 who
did not (p = 0.28). In the 26 patients who progressed at least one
EDSS point the mean concentration was 31.68 (1.39) mmol/L and
32.74 (0.94) mmol/L in the 60 stable patients (p = 0.54). We did
not detect any significant association between the mean concen-
tration of alpha-tocopherol and the occurrence of relapses when
stratified by IFNB treatment.
Discussion
We found that during IFNB treatment, increasing serum
concentrations of alpha-tocopherol were associated with reduced
odds for simultaneous and subsequent MRI disease activity. The
results were not noticeably influenced by gender, age, BMI, HLA-
DRB1*15 status, treatment group or compliance (omega-3 fatty
acids or placebo), or the concentrations of NAb against IFNB, 25-
hydroxyvitamin D, retinol, EPA or DHA.
Figure 1. Seasonal distribution of alpha-tocopherol concentra-
tions in serum during the whole study period. All 780 alpha-
tocopherol measurements from 88 patients clustered to the calendar
month of sampling. Error bars represent SD.
doi:10.1371/journal.pone.0054417.g001
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Studies regarding vitamin E and MS are relatively few. In small
cross-sectional studies, lower concentrations of both vitamin E and
vitamin E/cholesterol-ratio have been reported in stable MS
patients compared to controls [18], and also in MS patients during
exacerbation compared to stable MS patients with or without
IFNB treatment, and controls [9,19,20]. In a prospective study,
the risk of developing MS was not associated with total or dietary
intake of vitamin E [21]. To our knowledge, there are no
prospective studies addressing the relationship between vitamin E
and MRI disease activity in MS.
Our patient cohort comprises well characterized RRMS
patients examined with repeated MRI scans and serum measure-
ments, allowing eight paired MRI/alpha tocopherol assessments,
and is well suited for a prospective study of the relationship
between vitamin E and MS disease activity. Moreover, simulta-
neous measurements of vitamin A, vitamin D, DHA, EPA and
NAb against IFNB in the same patients, combined with records of
the compliance of study medication, enabled us to adjust for
potential confounding. However, our study also has limitations.
Although several paired MRI scans and serum measurements of
alpha-tocopherol were conducted in each patient, the cohort
might have been too small to detect minor, but nevertheless
potentially important associations with relapse rate and EDSS
progression. The dietary habits including use of vitamin supple-
ments were not recorded. Moreover, the patients received either
approximately 13 or 22 mg alpha-tocopherol from the omega-3 or
placebo preparations. This constitutes 2–3 times the intake of total
vitamin E estimated in a Finnish study [22], and also the estimated
average daily intake of vitamin E in Norway (8–10 alpha-
tocopherol equivalents, corresponding to 8–10 mg alpha-tocoph-
erol) [23]. Only the baseline values are therefore representative for
the habitual vitamin E status of the patients. Accordingly, there
was an increase in the mean concentration of alpha-tocopherol
from baseline to the rest of the study period, and the
supplementation might therefore have evened out both the inter-
and intra-individual variation. Even so, we found a mean ratio
between the highest and the lowest concentration of alpha-
tocopherol in each patient of 1.34 and 22.8% of the total variation
was accounted for by intra-individual variation. The serum
concentration of alpha-tocopherol is correlated to the concentra-
tion of lipoproteins [2,24]. Unfortunately, we did not measure
lipoproteins or total cholesterol, and can therefore not exclude that
lipoproteins might have confounded our results. However, in a
previous study T2 lesion volume was not associated with
lipoprotein concentrations [25], and the association with new T2
lesions was not influenced by BMI or omega-3 fatty acids in our
study. It is therefore less likely that lipoprotein status have
confounded the results.
Vitamin E has both antioxidative, immunomodulatory and
neuroprotective properties [3,7,26]. Our results are therefore
biologically plauisible. Immune cells produce ROS, which may
contribute to neuroinflammation in experimental allergic enceph-
alomyelitis [27] and MS [28,29]. Vitamin E has also been shown
to have other properties including regulation of enzymatic activity
and gene transcription [2] that might be relevant in MS [30,31],
and to have immunomodulatory properties in animal models of
rheumatoid arthritis [26] and systemic lupus erythematosus [8].
Previous small studies have reported an increase of alpha-
tocopherol in erythrocytes and plasma of MS patients treated with
IFNB [9,10], as well as normalisation of ROS production in
mononuclear cells [32]. The finding that the odds for new MRI
disease activity were only significantly reduced during IFNB
Table 1. Odds ratio for MRI outcomes for each 10 mmol/L increase in alpha-tocopherol.
Whole study period (88 patients)a Prior to IFNB (88 patients)b During IFNB (88 patients)c
MRI outcomes Odds ratio (CI 95%) p-value Odds ratio (CI 95%) p-value Odds ratio (CI 95%) p-value
CUA 0.803 (0.584–1.103) 0.176 0.732 (0.461–1.164) 0.186 0.646 (0.423–0.984) 0.042
New T2 lesions 0.737 (0.537–1.011) 0.059 0.682 (0.450–1.034) 0.071 0.632 (0.402–0.995) 0.048
New T1Gd+ lesions 0.838 (0.598–1.174) 0.305 0.787 (0.511–1.212) 0.275 0.651 (0.403–1.053) 0.080
a587 alpha-tocopherol/MRI pairs,
b254 alpha-tocopherol/MRI pairs,
c333 alpha-tocopherol/MRI pairs.
doi:10.1371/journal.pone.0054417.t001
Table 2. Odds ratio for lagged MRI outcomes for each 10 mmol/L increase in alpha-tocopherol.
Whole study perioda Prior to IFNBb During IFNBc
MRI outcomes Odds ratio (CI 95%) p-value Odds ratio (CI 95%) p-value Odds ratio (CI 95%) p-value
CUA Lag 1 month 0.835 (0.564–1.235) 0.365 0.730 (0.450–1.185) 0.202 0.878 (0.535–1.435) 0.596
Lag 2 months 0.855 (0.582–1.258) 0.426 0.907 (0.562–1.463) 0.688 0.659 (0.366–1.188) 0.163
New T2 lesions Lag 1 month 0.779 (0.541–1.122) 0.179 0.681 (0.426–1.088) 0.107 0.840 (0.508–1.390) 0.493
Lag 2 months 0.773 (0.535–1.116) 0.169 0.917 (0.607–1.386) 0.680 0.390 (0.174–0.876) 0.023
New T1Gd+ lesions Lag 1 month 0.738 (0.495–1.100) 0.135 0.632 (0.379–1.053) 0.078 0.824 (0.490–1.386) 0.462
Lag 2 months 0.731 (0.473–1.074) 0.105 0.834 (0.525–1.325) 0.440 0.346 (0.143–0.835) 0.019
aWhole study period: Lag 1:88 patients, 419 observations, Lag 2:88 patients, 420 observations.
bPrior to IFNB: Lag 1:88 patients, 250 observations, Lag 2:88 patients, 251 observations.
cDuring IFNB: Lag 1:86 patients, 169 observations, Lag 2:87 patients, 169 observations.
doi:10.1371/journal.pone.0054417.t002
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treatment could indicate an interaction between IFNB and
vitamin E. However, the difference in odds reduction before and
during IFNB treatment was modest, and adjusting for NAb against
IFNB did not alter our results. Thus, there is not sufficient
evidence to draw any conclusion, and a possible interaction
between vitamin E and IFNB treatment should be studied in a
larger cohort.
In conclusion, we have shown an association between increasing
alpha-tocopherol concentrations and simultaneous and subsequent
MRI disease activity in RRMS patients during treatment with
IFNB. The relation between vitamin E and MS should be further
investigated in epidemiological and experimental studies.
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